Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance

Background: Anti–amyloid-β (Aβ) therapies can slow cognitive decline and reduce cerebral amyloid burden in Alzheimer’s disease (AD). Neuropsychiatric symptoms (NPS) are highly prevalent across the disease course and substantially contribute to disability and caregiver burden. However, whether Aβ cle...

Full description

Bibliographic Details

Main Authors:	Yaping Yan, Daoyan Hu, Linlin Kong, Kaicheng Li, Jun Su, Yingzhe Wu, Hongwei Zhan, Hong Zhang, Yidan Sun, Xiaofeng Dou, Peiyu Huang, Jiong Zhou
Format:	Artigo
Language:	Inglês
Published:	Elsevier 2026-08-01
Series:	The Journal of Prevention of Alzheimer's Disease
Subjects:	Alzheimer’s disease Lecanemab Neuropsychiatric symptoms Aβ clearance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2274580726001251
Tags:	Add Tag No Tags, Be the first to tag this record!